Christensen Klaus, Roudnicky Filip, Patsch Christoph, Burcin Mark
Roche pRED (Pharmaceutical Research and Early Development), Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd., Basel, Switzerland.
Adv Biochem Eng Biotechnol. 2018;163:207-220. doi: 10.1007/10_2017_23.
A prevalent challenge in drug discovery is the translation of findings from preclinical research into clinical success. Currently, more physiological in vitro systems are being developed to overcome some of these challenges. In particular, induced pluripotent stem cells (iPSCs) have provided the opportunity to generate human cell types that can be utilized for developing more disease-relevant cellular assay models. As the use of these complex models is lengthy and fairly complicated, we lay out our experiences of the cultivation, differentiation, and quality control requirements to successfully utilize pluripotent stem cells in drug discovery.
药物研发中一个普遍存在的挑战是将临床前研究的结果转化为临床成功。目前,正在开发更多生理性的体外系统来克服其中一些挑战。特别是,诱导多能干细胞(iPSC)为生成可用于开发更具疾病相关性的细胞检测模型的人类细胞类型提供了机会。由于使用这些复杂模型的过程漫长且相当复杂,我们阐述了在药物研发中成功利用多能干细胞的培养、分化及质量控制要求方面的经验。